Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ariel Discovery Fund Institutional Class (ADYIX)

9.83
Net Asset Value
-1.40%
1 Day
-3.82%
Year-to-Date
Overall Morningstar Rating
Small value
Style or Category
No Load
Sales Expenses
1.40%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund invests in small/micro cap companies that are selling at deep discounts to their intrinsic value. It invests primarily in equity securities of U.S. companies with market capitalizations under $2 billion, measured at the time of initial purchase. Also, the market capitalizations for the fund's portfolio companies may change over time, and the fund is permitted to invest in (hold and purchase) a company even if its market capitalization moves above $2 billion.

Performance

1 month-6.74% 3 years-3.56%
3 months-4.68% 5 years+2.31%
1 year+7.67% Since inception+5.24%
Data through --

Peer Comparisonvs. Small value

 ADYIXCategory
Performance 5-yr return+2.31%+12.47%
Expense ratio1.40%1.31%
Risk 5 year sharpe ratio0.290.97
Net assets$40.1M$1.0B
Average market cap$289.5M$2.9B
Average P/E--18.7
Portfolio turnover45%45%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAriel Investments, LLC
Fund manager & tenureKenneth Kuhrt / 6 Years
Minimal initial investment$1,000,000.00
Minimum IRA investment--

Holdings

U.S. stock93.69%
Cash5.71%
Fixed income0.60%
International stock0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
COWN Cowen Inc5.67%
RST Rosetta Stone Inc5.08%
RNWK RealNetworks Inc5.00%
ORBC ORBCOMM Inc4.50%
CNTY Century Casinos Inc4.29%
PCTI PCTEL Inc3.43%
XOXO XO Group Inc3.39%
TNAV Telenav Inc3.35%
FAF First American Financial Corp3.29%
KIN Kindred Biosciences Inc3.08%